136 related articles for article (PubMed ID: 37890590)
21. Retrovirus-mediated gene transfer in polyclonal T cells results in lower apoptosis and enhanced ex vivo cell expansion of CMV-reactive CD8 T cells as compared with EBV-reactive CD8 T cells.
Sauce D; Rufer N; Mercier P; Bodinier M; Rémy-Martin JP; Duperrier A; Ferrand C; Hervé P; Romero P; Lang F; Tiberghien P; Robinet E
Blood; 2003 Aug; 102(4):1241-8. PubMed ID: 12730101
[TBL] [Abstract][Full Text] [Related]
22. Hematopoietic stem cell transplantation across major genetic barriers: tolerance induction by megadose CD34 cells and other veto cells.
Reisner Y; Gur H; Reich-Zeliger S; Martelli MF; Bachar-Lustig E
Ann N Y Acad Sci; 2003 May; 996():72-9. PubMed ID: 12799285
[TBL] [Abstract][Full Text] [Related]
23. Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant.
Jiang W; Clancy LE; Avdic S; Sutrave G; Street J; Simms R; McGuire HM; Patrick E; Chan AS; McCaughan G; Myers N; Micklethwaite KP; Antonenas V; Selim AG; Ritchie D; Bateman CM; Shaw PJ; Blyth E; Gottlieb DJ
Blood Adv; 2022 Sep; 6(17):4949-4966. PubMed ID: 35819448
[TBL] [Abstract][Full Text] [Related]
24. Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes.
Hartwig UF; Nonn M; Khan S; Meyer RG; Huber C; Herr W
Bone Marrow Transplant; 2006 Feb; 37(3):297-305. PubMed ID: 16327814
[TBL] [Abstract][Full Text] [Related]
25. Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.
Qian C; Campidelli A; Wang Y; Cai H; Venard V; Jeulin H; Dalle JH; Pochon C; D'aveni M; Bruno B; Paillard C; Vigouroux S; Jubert C; Ceballos P; Marie-Cardine A; Galambrun C; Cholle C; Clerc Urmes I; Petitpain N; De Carvalho Bittencourt M; Decot V; Reppel L; Salmon A; Clement L; Bensoussan D
J Hematol Oncol; 2017 May; 10(1):102. PubMed ID: 28482908
[TBL] [Abstract][Full Text] [Related]
26. Removal of CD276
Hashimoto H; Kasteleiner P; Kressin J; Müller F; Bühring HJ; Handgretinger R; Schilbach K
Bone Marrow Transplant; 2021 Oct; 56(10):2336-2354. PubMed ID: 33976380
[TBL] [Abstract][Full Text] [Related]
27. A strategy to protect off-the-shelf cell therapy products using virus-specific T-cells engineered to eliminate alloreactive T-cells.
Quach DH; Becerra-Dominguez L; Rouce RH; Rooney CM
J Transl Med; 2019 Jul; 17(1):240. PubMed ID: 31340822
[TBL] [Abstract][Full Text] [Related]
28. Naive T cells inhibit the outgrowth of intractable antigen-activated memory T cells: implications for T-cell immunotherapy.
Sharma S; Woods M; Mehta NU; Sauer T; Parikh KS; Schmuck-Henneresse M; Zhang H; Mehta B; Brenner MK; Heslop HE; Rooney CM
J Immunother Cancer; 2023 Apr; 11(4):. PubMed ID: 37072346
[TBL] [Abstract][Full Text] [Related]
29. Identification of stem cell transcriptional programs normally expressed in embryonic and neural stem cells in alloreactive CD8+ T cells mediating graft-versus-host disease.
Kato K; Cui S; Kuick R; Mineishi S; Hexner E; Ferrara JL; Emerson SG; Zhang Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):751-71. PubMed ID: 20116439
[TBL] [Abstract][Full Text] [Related]
30. The role of early natural killer cell adoptive infusion before engraftment in protecting against human herpesvirus-6B encephalitis after naïve T-cell-depleted allogeneic stem cell transplantation.
Gasior M; Ferreras C; de Paz R; Bueno D; Mozo Y; Sisinni L; Canizales JT; González B; Olivas-Mazón R; Marcos A; Romero AB; Constanzo A; Mirones I; Fernández-Arroyo A; Balas A; Vicario JL; Escudero A; Yuste VJ; Pérez-Martínez A
Transfusion; 2021 May; 61(5):1505-1517. PubMed ID: 33713461
[TBL] [Abstract][Full Text] [Related]
31. Alloreactive and leukemia-reactive T cells are preferentially derived from naive precursors in healthy donors: implications for immunotherapy with memory T cells.
Distler E; Bloetz A; Albrecht J; Asdufan S; Hohberger A; Frey M; Schnürer E; Thomas S; Theobald M; Hartwig UF; Herr W
Haematologica; 2011 Jul; 96(7):1024-32. PubMed ID: 21486863
[TBL] [Abstract][Full Text] [Related]
32. Human lymphokine activated killer (LAK) cells suppress generation of allospecific cytotoxic T cells: implications for use of LAK cells to prevent graft-versus-host disease in allogeneic bone marrow transplantation.
Uberti J; Martilotti F; Chou TH; Kaplan J
Blood; 1992 Jan; 79(1):261-8. PubMed ID: 1370206
[TBL] [Abstract][Full Text] [Related]
33. Lowest numbers of primary CD8(+) T cells can reconstitute protective immunity upon adoptive immunotherapy.
Stemberger C; Graef P; Odendahl M; Albrecht J; Dössinger G; Anderl F; Buchholz VR; Gasteiger G; Schiemann M; Grigoleit GU; Schuster FR; Borkhardt A; Versluys B; Tonn T; Seifried E; Einsele H; Germeroth L; Busch DH; Neuenhahn M
Blood; 2014 Jul; 124(4):628-37. PubMed ID: 24855206
[TBL] [Abstract][Full Text] [Related]
34. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.
Lee DA; Denman CJ; Rondon G; Woodworth G; Chen J; Fisher T; Kaur I; Fernandez-Vina M; Cao K; Ciurea S; Shpall EJ; Champlin RE
Biol Blood Marrow Transplant; 2016 Jul; 22(7):1290-1298. PubMed ID: 27090958
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of graft-versus-host disease by interleukin-2 treatment is associated with altered cytokine production by expanded graft-versus-host-reactive CD4+ helper cells.
Wang MG; Szebeni J; Pearson DA; Szot GL; Sykes M
Transplantation; 1995 Sep; 60(5):481-90. PubMed ID: 7676498
[TBL] [Abstract][Full Text] [Related]
36. CMV-, EBV- and ADV-specific T cell immunity: screening and monitoring of potential third-party donors to improve post-transplantation outcome.
Sukdolak C; Tischer S; Dieks D; Figueiredo C; Goudeva L; Heuft HG; Verboom M; Immenschuh S; Heim A; Borchers S; Mischak-Weissinger E; Blasczyk R; Maecker-Kolhoff B; Eiz-Vesper B
Biol Blood Marrow Transplant; 2013 Oct; 19(10):1480-92. PubMed ID: 23891747
[TBL] [Abstract][Full Text] [Related]
37. Protective immunity transferred by infusion of cytomegalovirus-specific CD8(+) T cells within donor grafts: its associations with cytomegalovirus reactivation following unmanipulated allogeneic hematopoietic stem cell transplantation.
Luo XH; Huang XJ; Liu KY; Xu LP; Liu DH
Biol Blood Marrow Transplant; 2010 Jul; 16(7):994-1004. PubMed ID: 20167279
[TBL] [Abstract][Full Text] [Related]
38. Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy.
Wang Y; Aïssi-Rothe L; Virion JM; De Carvalho Bittencourt M; Ulas N; Audonnet S; Salmon A; Clement L; Venard V; Jeulin H; Stoltz JF; Decot V; Bensoussan D
Cytotherapy; 2014 Jan; 16(1):122-34. PubMed ID: 24094498
[TBL] [Abstract][Full Text] [Related]
39. Specificity of T cells in synovial fluid: high frequencies of CD8(+) T cells that are specific for certain viral epitopes.
Tan LC; Mowat AG; Fazou C; Rostron T; Roskell H; Dunbar PR; Tournay C; Romagné F; Peyrat MA; Houssaint E; Bonneville M; Rickinson AB; McMichael AJ; Callan MF
Arthritis Res; 2000; 2(2):154-64. PubMed ID: 11062606
[TBL] [Abstract][Full Text] [Related]
40. Alloreactive memory T cells are responsible for the persistence of graft-versus-host disease.
Zhang Y; Joe G; Hexner E; Zhu J; Emerson SG
J Immunol; 2005 Mar; 174(5):3051-8. PubMed ID: 15728519
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
